Search
Besigomsin
go.drugbank.com/drugs/DB20894ExperimentalBesigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.
Categories: Compounds used in a research, industrial, or household settingAM336
go.drugbank.com/drugs/DB06563ExperimentalIt was investigated as a potential treatment for various pain conditions. … Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.
Categories: Calcium Channels, N-TypeIGN311
go.drugbank.com/drugs/DB04988ExperimentalIGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
KAND567
go.drugbank.com/drugs/DB16511InvestigationalBecause COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].
Viper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
SAR-260301
go.drugbank.com/drugs/DB33608InvestigationalCategories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsDescartes-30
go.drugbank.com/drugs/DB16361InvestigationalDescartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. … [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.